Dipyridamole Induced Ischemia and Biomarkers

Analysis of certain biomarkers and transient myocardial perfusion deficit revealed by myocardial perfusion scintigraphy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ischemic Heart Disease Cardiovascular Diseases Heart Diseases Ischemic Attack Myocardial Ischemia Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Pecs

Pécs, Baranya, 7624, Hungary

About this study

The prospectively enrolled patients were followed up to 5 years. Adverse major events (MI, stroke, death) suffered during follow-up were retrospectively analysed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1. written informed consent. 2. clinical diagnosis of ischemic heart disease (IHD) -

Exclusion criteria

1. refused written informed consent. 2. lost data during follow-up

Treatment and study plan

Myocardial perfusion scintigraphy

Diagnostic Test

Myocardial perfusion scintigraphy as it is described in the international literature.

Primary outcomes

Myocardial perfusion abnormality

Time frame: 5 year follow-up after MPS

Myocardial perfusion was quantified based on myocardial perfusion scintigraphy (MPS).

Sponsors and collaborators

Lead sponsor

University of Pecs

Other

Registry information

Official study title

Relationship Between the L-arginine Pathway Metabolites and Dipyridamole Stress Induced Transient Myocardial Ischaemia

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2017
First posted: Sep 28, 2018
Registry last updated: Sep 28, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed